LAUSR

ABSTRACT The magadiite (MAG) was modified by cetyltrimethyl ammonium‐Bromide (CTAB) and then further modified by Chitosan (CS) which is called organic modified‐magadiite as magadiite‐cetyltrimethyl ammonium bromide (MAG‐CTAB) and magadiite‐cetyltrimethyl ammonium bromide‐Chitosan (MAG‐CTAB‐CS), respectively, in this research study. The MAG, MAG‐CTAB, and MAG‐CTAB‐CS were used as 5‐Fluorouracil (5‐FU) drug carrier materials; the drug carrier's materials were marked as magadiite‐5‐Fluorouracil (MAG/5‐FU), magadiite‐cetyltrimethyl ammonium bromide‐5‐Fluorouracil (MAG‐CTAB/5‐FU), and magadiite‐cetyltrimethyl ammonium bromide‐Chitosan (MAG‐CTAB‐CS/5‐FU). X‐ray diffraction(XRD, Flourier transform infrared spectrometry (FTIR) and scanning electron microscopy (SEM) results were shown that 5‐Fluorouracil was combined with carrier materials through physical apparent adsorption, ion exchange, chemical bond, hydrogen bond, and electrostatic interaction. The drug carriers in vitro release behavior in simulated gastric fluids (SGF, pH=1.35) and intestinal fluids (SIF, pH=7.40) were investigated. The drug loading capacity and accumulated release ration were as follows the order: MAG‐CTAB‐CS/5‐FU>MAG‐CTAB/5‐FU>MAG/5‐FU. The drug loading capacity of MAG‐CTAB‐CS/5‐FU was 162.29mg/g, 48h later the drug accumulated release ratio was 61.24%, and the release amount was 97.52mg/g for 24h. Korsmeyer‐Peppas model and First order model were found to be suitable to describe the vitro release behavior of 5‐Fluorouracil. This would be an economically viable and efficient method for the preparation of advanced drug delivery system.